Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial
| Autor: | Gemma García-Parés, Javier Labad, Christian Núñez, Marta Creus, Jesús Cobo, José Franco, Elena Huerta-Ramos, Julio-César Reyes, Eva Miquel, Daniel Cuadras, Silvia Marcó-García, Judith Usall |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Selective Estrogen Receptor Modulators
medicine.medical_specialty Placebo-controlled study Placebo Executive Function 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine Humans Medicine Attention Cognitive Dysfunction Pharmacology (medical) Raloxifene Biological Psychiatry Aged Memory Disorders medicine.diagnostic_test business.industry Cognition General Medicine Neuropsychological test Middle Aged 030227 psychiatry Postmenopause Clinical trial Psychiatry and Mental health Exact test Treatment Outcome Raloxifene Hydrochloride Schizophrenia Mann–Whitney U test Drug Therapy Combination Female business 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | European Archives of Psychiatry and Clinical Neuroscience. 270:729-737 |
| ISSN: | 1433-8491 0940-1334 |
| DOI: | 10.1007/s00406-019-01079-w |
| Popis: | We assessed the utility of raloxifene (60 mg/day) as an adjuvant treatment for cognitive symptoms in postmenopausal women with schizophrenia in a 24-week, double-blind, randomized, placebo-controlled study. Patients were recruited from the inpatient and outpatient services of Parc Sanitari Sant Joan de Deu, Hospital Universitari Institut Pere Mata, and Corporacio Sanitaria Parc Tauli. Seventy eight postmenopausal women with schizophrenia were randomized to either adjunctive raloxifene or placebo. Sixty-eight began the clinical trial (37 women on raloxifene adjunct) and 31 on placebo adjunct. The outcome measures were: memory, attention and executive function. Assessment was conducted at baseline and at week 24. Between groups homogeneity was tested with the Student's t test for continuous variables and/or the Mann–Whitney U test for ordinal variables and the χ2 test or Fisher's exact test for categorical variables. The differences between the two groups in neuropsychological test scores were compared using the Student's t test. The sample was homogenous with respect to age, formal education, illness duration and previous pharmacological treatment. The addition of raloxifene to antipsychotic treatment as usual showed no differences in cognitive function. The daily use of 60 mg raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia has no appreciable effect. ClinicalTrials.gov Identifier: NCT01573637. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink